

Genetic causes of cardiac arrest in patients with first heart attack

Submission date 03/11/2016	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/12/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 25/09/2017	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Sudden cardiac death (SCD) caused by ventricular fibrillation (VF) during a heart attack (cardiac arrest) is a leading cause of natural death worldwide. VF is a heart rhythm problem where the heart beats so rapidly and erratically, causing the chambers of the heart to quiver uselessly rather than pump blood around the body. Studies have shown that there is a genetic (inherited) component, indicating that sudden death of a family member is a risk factor for SCD and VF. Even though new insights and technology have become available, the nature of this remains poorly understood. Understanding the underlying genetic causes of SCD and VF would be a valuable means of being any to predict and prevent development of VF and develop new treatments. This study aims to evaluate the genetic components associated with VF in order to understand the underlying mechanisms.

Who can participate?

Adults having their first ST-elevations MI (STEMI – a type of heart attack) with and without VF within the first 12 hours.

What does the study involve?

Participants are recruited at the point of their STEMI. At this time, information about the participants and their medical history is collected by the researchers using questionnaires. If any information is missing, then the researchers have permission to contact the participants after they are discharged from hospital. While they are in hospital, a blood sample is collected to use for genetic analysis. After they are discharged, participants are followed up for five years to look for death of any cause by reviewing Danish nationwide registries and medical records.

What are the possible benefits and risks of participating?

There are no direct benefits or risks involved with participating.

Where is the study run from?

1. University Hospital of Copenhagen (Denmark)
2. Odense University Hospital (Denmark)
3. Aarhus University Hospital, Skejby (Denmark)
4. Aalborg University Hospital (Denmark)

When is the study starting and how long is it expected to run for?
July 2010 to July 2023

Who is funding the study?

1. The John and Birthe Meyer Foundation (Denmark)
2. The Novo Nordisk Foundation (Denmark)

Who is the main contact?

Dr Jacob Tfelt-Hansen

Contact information

Type(s)

Scientific

Contact name

Dr Jacob Tfelt-Hansen

Contact details

The Heart Centre
Department of Cardiology
University Hospital of Copenhagen
Rigshospitalet
Blegdamsvej 9
Copenhagen
Denmark
2100

Additional identifiers

Protocol serial number

H-3-2010-133

Study information

Scientific Title

Genetic causes of Ventricular Arrhythmias in patients with first STEMI (GEVAMI) study

Acronym

GEVAMI

Study objectives

1. Genetic factors play a significant role in ventricular fibrillation (VF) caused by first ST-elevation myocardial infarction (STEMI)
2. VF during ischemia has a multifactorial and complex nature with a familial aggregation, implicating a genetic cause.

Ethics approval required

Old ethics approval format

Ethics approval(s)

National Committee on Health Research Ethics, 25/05/2011, protocol number: H-3-2010-133

Study design

Nationwide prospective case-control study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Ventricular fibrillation

Interventions

Participants are recruited at the point of first STEMI. Baseline demographics and previous medical history are collected by researchers by using standardized questionnaires while the participant is in hospital. If data was missing in the questionnaires, the researchers have permission to contact the patient after the discharge. In addition, medical records are collected and the comprehensive Danish nationwide registries are used to describe comorbidities and for follow up. Blood sample is collected during hospitalisation, often at the same time as participants undergo routine blood testing. This is used for future genetic analysis.

Participants are followed up continuously for 5 years by reviewing Danish registries to assess for all-cause mortality.

Intervention Type

Other

Primary outcome(s)

Common and rare genetic variants associated with ventricular fibrillation (VF) during first ST-elevation myocardial infarction (STEMI), analysed by genome-wide association studies and next generation sequencing

Key secondary outcome(s)

All-cause mortality is measured using the Danish registries continuously for 5 years

Completion date

03/07/2023

Eligibility

Key inclusion criteria

Cases

1. First STEMI patients who experienced VF within the first 12 hours of symptoms of STEMI before PPCI
2. Age between 18 and 80 years

3. Caucasians
4. Cardiac symptoms lasting ≤ 12 hours
5. Acute ST-segment elevation revealed by ECG

Controls:

1. First STEMI patients who did not have VF during the first 12 hours of symptoms of STEMI before PPCI
2. Age between 18 and 80 years
3. Caucasians
4. Cardiac symptoms lasting ≤ 12 hours
5. Acute ST-segment elevation revealed by ECG

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Cases and controls who developed VF during PPCI will be excluded because VF during PPCI is believed to be reperfusion induced; however, case patients with VF before PPCI who continued to have VF during PPCI can participate
2. Other exclusions included VF after PPCI
3. Congenital heart defects
4. Known structural heart disease
5. Use of class I and III antiarrhythmic drugs
6. Recent cancer
7. Major surgery or trauma within 4 weeks
8. Presentation with potassium concentration of <3 or >5 mmol/L
9. Because we also planned to identify genetic markers associated with VF, and because $>90\%$ of the Danish populations are white Danes, we excluded non-white Danes to reduce the risk of population stratification for future genetic analysis

Date of first enrolment

03/07/2011

Date of final enrolment

03/07/2020

Locations

Countries of recruitment

Denmark

Study participating centre

University Hospital of Copenhagen

The Heart Centre

Department of Cardiology

Rigshospitalet

Blegdamsvej 9

Copenhagen

Denmark

2100

Study participating centre

Odense University Hospital

Department of Cardiology

Søndre Blvd. 29

Odense

Denmark

5000

Study participating centre

Aarhus University Hospital, Skejby

Department of Cardiology

Palle Juul-Jensens Blvd. 99

Aarhus

Denmark

8200

Study participating centre

Aalborg University Hospital

Department of Cardiology

Hobrovej 18-22

Aalborg

Denmark

9100

Sponsor information

Organisation

University Hospital of Copenhagen

ROR

<https://ror.org/05bpbnx46>

Funder(s)

Funder type

Charity

Funder Name

The John and Birthe Meyer Foundation

Funder Name

The Novo Nordisk Foundation

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	05/01/2015		Yes	No